Johnson & Johnson Wins FDA Nod for New Multiple Myeloma Therapy

Seekingalpha2023-08-11

The Janssen Pharmaceutical unit of Johnson & Johnson announced Thursday that the U.S. FDA granted accelerated approval for its bispecific antibody Talvey as a late-line option for adults with relapsed...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2358723041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-08-11 10:47","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2358723041","market":"us","top_or_hot":-1,"title":"Johnson & Johnson Wins FDA Nod for New Multiple Myeloma Therapy","media":"Seekingalpha","content":"<div>\n<p>The Janssen Pharmaceutical unit of Johnson & Johnson announced Thursday that the U.S. FDA granted accelerated approval for its bispecific antibody Talvey as a late-line option for adults with relapsed...</p>\n\n<a href=\"https://seekingalpha.com/news/4000875-johnson-johnson-wins-fda-nod-multiple-myeloma-therapy\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Wins FDA Nod for New Multiple Myeloma Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Wins FDA Nod for New Multiple Myeloma Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-11 10:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4000875-johnson-johnson-wins-fda-nod-multiple-myeloma-therapy><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Janssen Pharmaceutical unit of Johnson & Johnson announced Thursday that the U.S. FDA granted accelerated approval for its bispecific antibody Talvey as a late-line option for adults with relapsed...</p>\n\n<a href=\"https://seekingalpha.com/news/4000875-johnson-johnson-wins-fda-nod-multiple-myeloma-therapy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://seekingalpha.com/news/4000875-johnson-johnson-wins-fda-nod-multiple-myeloma-therapy","article_id":"2358723041","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2358723041","pubTimestamp":1691722046,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The Janssen Pharmaceutical unit of Johnson & Johnson (NYSE:JNJ) announced Thursday that the U.S. FDA granted accelerated approval for its bispecific antibody Talvey as a late-line option for adults wi","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"强生公司获得FDA对多发性骨髓瘤新疗法的认可","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"The Janssen Pharmaceutical unit of Johnson & Johnson announced Thursday that the U.S. FDA granted accelerated approval for its bispecific antibody Talvey as a late-line option for adults with relapsed or refractory multiple myeloma.Accordingly, the drug, also known as talquetamab-tgvs, will be available in the U.S. as a weekly or biweekly subcutaneous injection for adults with R/R multiple myeloma who have previously undergone at least four lines of therapy.Given that Talvey is approved under the FDA’s accelerated path based on response rate and durability of response, the company will have to prove its benefit using confirmatory trial(s).Talvey comes with a Boxed Warning for safety concerns, cytokine release syndrome and neurologic toxicity, and the treatment will be available only through the FDA safety program, Risk Evaluation and Mitigation Strategy (REMS).Tecvayli, a bispecific antibody developed by Janssen in partnership with Ligand Pharmaceuticals (LGND), was granted FDA accelerated approval in 2022 as a late-line option for adults with R/R multiple myeloma.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2358723041"}